Related Experiment Videos
Serum urate levels and gout flares: analysis from managed care data
Chaitanya A Sarawate1, Pankaj A Patel, H Ralph Schumacher
1Health Outcomes Research, HealthCore, Inc., 800 Delaware Avenue, Wilmington, DE 19801-1366, USA. csarawate@healthcore.com
Summary
Many gout patients on allopurinol do not reach target serum urate levels, increasing their risk of gout flares. Achieving target serum urate is crucial for preventing gout attacks.
Area of Science:
- Rheumatology
- Pharmacoeconomics
- Clinical Pharmacy
Background:
- The recommended serum urate level (SUA) for gout attack prevention is below 6.0 mg/dL.
- Attaining this target SUA is essential for effective gout management.
Purpose of the Study:
- To evaluate the achievement of target SUA in gout patients using allopurinol in a real-world setting.
- To assess the impact of target SUA attainment on gout flare risk.
Main Methods:
- Retrospective observational study of 5942 gout patients within a managed care organization.
- Analysis of allopurinol use, serum urate levels, and gout flare incidence.
- Multivariable regression models to determine flare risk associated with target SUA.
Main Results:
- Only 25% of allopurinol users not at target SUA pre-index achieved target levels post-index.
- Patients not at target SUA were 59% more likely to experience gout flares.
- Allopurinol users failing to reach target SUA had a 75% increased likelihood of flares.
Conclusions:
- Failure to achieve target SUA in gout patients on allopurinol is common.
- Factors contributing to this include dosing, compliance, and awareness of SUA goals.
- Suboptimal SUA levels significantly elevate the risk of recurrent gout flares.